Mebeverine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Mebeverine is an antispasmodic used for the symptomatic treatment of stomach pain and spasms associated with irritable bowel syndrome and other gastrointestinal illnesses.

Generic Name
Mebeverine
DrugBank Accession Number
DB12554
Background

Mebeverine has been investigated for the treatment of Irritable Bowel Syndrome and Post-cholecystectomy Gastrointestinal Spasms.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Weight
Average: 429.557
Monoisotopic: 429.251523231
Chemical Formula
C25H35NO5
Synonyms
  • Mebeverina
  • Mebeverine
  • Mebeverinum
External IDs
  • BRN 2783282

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination for symptomatic treatment ofAbdominal painCombination Product in combination with: Simethicone (DB09512)•••••••••••••••••••• •••••• ••••••
Used in combination for symptomatic treatment ofAbdominal spasmsCombination Product in combination with: Simethicone (DB09512)•••••••••••••••••••• •••••• ••••••
Used in combination for symptomatic treatment ofAbnormal bowel movement such as constipation, diarrhea, abdominal painCombination Product in combination with: Simethicone (DB09512)•••••••••••••••••••• •••••• ••••••
Symptomatic treatment ofIrritable bowel syndrome (ibs)•••••••••••••••••••
Used in combination for symptomatic treatment ofBowel discomfortCombination Product in combination with: Simethicone (DB09512)•••••••••••••••••••• •••••• ••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcipimoxThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Acipimox is combined with Mebeverine.
AclidiniumThe risk or severity of adverse effects can be increased when Mebeverine is combined with Aclidinium.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with Mebeverine.
Alendronic acidThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Mebeverine.
AlfentanilThe risk or severity of adverse effects can be increased when Mebeverine is combined with Alfentanil.
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Mebeverine hydrochloride15VZ5AL4JN2753-45-9PLGQWYOULXPJRE-UHFFFAOYSA-N
International/Other Brands
Colofac / Duspatal / Duspatalin / Rudakol
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
DUSPATALIN RETARD CAPSULE 200 mgCapsule200 mgOralABBOTT LABORATORIES (SINGAPORE ) PRIVATE LIMITED1994-10-03Not applicableSingapore flag
MEBETIN TABLET 135 mgTablet, sugar coated135 mgOralZYFAS PHARMA PTE LTD1998-09-07Not applicableSingapore flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ARLUY DUOMebeverine hydrochloride (200 mg) + Simethicone (300 mg)Capsule, liquid filledOralCATALENT ARGENTINA. SOCIEDAD ANONIMA. INDUSTRIAL Y COMERCIAL2018-07-06Not applicableColombia flag

Categories

ATC Codes
A03AA04 — Mebeverine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as p-methoxybenzoic acids and derivatives. These are benzoic acids in which the hydrogen atom at position 4 of the benzene ring is replaced by a methoxy group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
P-methoxybenzoic acids and derivatives
Alternative Parents
M-methoxybenzoic acids and derivatives / Amphetamines and derivatives / Benzoic acid esters / Dimethoxybenzenes / Phenylpropanes / Phenoxy compounds / Anisoles / Benzoyl derivatives / Alkyl aryl ethers / Aralkylamines
show 7 more
Substituents
Alkyl aryl ether / Amine / Amino acid or derivatives / Amphetamine or derivatives / Anisole / Aralkylamine / Aromatic homomonocyclic compound / Benzoate ester / Benzoyl / Carboxylic acid derivative
show 20 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
7F80CC3NNV
CAS number
3625-06-7
InChI Key
VYVKHNNGDFVQGA-UHFFFAOYSA-N
InChI
InChI=1S/C25H35NO5/c1-6-26(19(2)17-20-9-12-22(28-3)13-10-20)15-7-8-16-31-25(27)21-11-14-23(29-4)24(18-21)30-5/h9-14,18-19H,6-8,15-17H2,1-5H3
IUPAC Name
4-{ethyl[1-(4-methoxyphenyl)propan-2-yl]amino}butyl 3,4-dimethoxybenzoate
SMILES
CCN(CCCCOC(=O)C1=CC(OC)=C(OC)C=C1)C(C)CC1=CC=C(OC)C=C1

References

General References
Not Available
PubChem Compound
4031
PubChem Substance
347828778
ChemSpider
3891
RxNav
29410
ChEBI
91514
ChEMBL
CHEMBL282121
Wikipedia
Mebeverine

Clinical Trials

Clinical Trials

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Capsule, liquid filledOral
CapsuleOral
CapsuleOral200.000 mg
Capsule, extended releaseOral
Tablet, coatedOral135 mg/1
Tablet, sugar coatedOral
Tablet, coatedOral100 mg
Capsule, extended releaseOral200 mg
SyrupOral10 mg/ml
SuspensionOral1.000 g
SuspensionOral1 g
Tablet, coatedOral135 mg
Tablet, film coatedOral
Tablet, delayed releaseOral200 mg
Tablet, sugar coatedOral135 mg
Capsule, delayed releaseOral200 mg
Tablet, film coatedOral135 MG
TabletOral135 mg
CapsuleOral200 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0029 mg/mLALOGPS
logP4.87ALOGPS
logP4.89Chemaxon
logS-5.2ALOGPS
pKa (Strongest Basic)10.31Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area57.23 Å2Chemaxon
Rotatable Bond Count14Chemaxon
Refractivity123.54 m3·mol-1Chemaxon
Polarizability49.66 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001i-0000900000-211570923a386119fb40
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-001j-0700900000-99c57564f3fc24c545e0
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-006t-0900000000-c0682f422d00560d08ba
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00di-0900000000-2e05532c5e033b444833
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00di-1900000000-932bf2e1c980e01c0e84
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00ea-0900300000-a95ec1fe9eb9355e870d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-001j-0347900000-ddcb95897e715b35ef0c
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-003j-0911300000-1cc0f40de6cd4ed95177
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-066r-0927000000-bda532b9228ee4d202e2
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00kr-0958100000-3a96ad5950bab7bee6c1
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0gbc-0911000000-88533e00df90d2f90de2
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-05a9-2915000000-07aec7d5f58f518a262f
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-206.61266
predicted
DeepCCS 1.0 (2019)
[M+H]+209.0218
predicted
DeepCCS 1.0 (2019)
[M+Na]+216.18297
predicted
DeepCCS 1.0 (2019)

Drug created at October 20, 2016 22:50 / Updated at June 08, 2021 11:32